Prof. Hiltrud Brauch came to the Dr. Margarete Fischer-Bosch-Institute of Clinical Pharmacology (IKP) in 1999 after completing her training in Molecular Genetics of Cancer and Habilitation in the field of Molecular Pathology. She has held positions of increasing responsibility at the National Cancer Institute (NCI), USA, the German Cancer Research Center, Heidelberg, the Technical University Munich (Klinikum rechts der Isar), the University of Hamburg, and the IKP Stuttgart.

During her postdoctoral training at the NCI, she was part of the team identifying the VHL Tumor Suppressor Locus and since then pursues a range of scientific interests including the Molecular Origin of Hereditary (VHL disease) and Sporadic Kidney Cancer. Within the last decade she has established a reputation within the field of Breast Cancer Susceptibility and Treatment Outcomes. At IKP she has expanded her research towards a strong focus on the Pharmacogenomics of Breast Cancer.

Prof. Brauch participates in a number of national and international research networks including the Gene Environment Interactions and Breast Cancer in Germany (GENICA), the Breast Cancer Association Consortium (BCAC) and the International Tamoxifen Consortium (ITPC). She coordinated the 5FP EU European Marie Curie PhD training site Stuttgart/Tübingen “Fighting Breast Cancer”, and teaches at the University of Tübingen. Currently she coordinates the 7FP EU Initial Training Network Fighting Drug Failure, which establishes the first European Curriculum in the field of Pharmacogenomics for young investigators.

Scientific accomplishments include more than 150 peer reviewed publications, including more than 220 original research articles.